CBD for Insomnia and Other Sleep Disorders: What Sleep Medicine Says 2026

Sleep disorders are not a single illness, but a whole family: psychogenic insomnia, sleep apnea, restless legs syndrome, parasomnias, narcolepsy, REM sleep behavior disorder. Each of them has a different pathophysiology and different recommended treatments. In Poland, symptoms of insomnia occur in about 50.5% of adults at least once a week, and chronic insomnia is diagnosed in 15-23% of the population (Journal of Sleep Research, 2020).

CBD is increasingly marketed as a universal solution for all sleep disorders. Meanwhile, sleep medicine is more nuanced. In obstructive sleep apnea (OSA), the American Academy of Sleep Medicine explicitly advises against cannabinoids (Journal of Clinical Sleep Medicine, 2018). In primary insomnia, the evidence is solid, but cognitive-behavioral therapy (CBT-I) remains the gold standard. In RLS, we only have case series.

This guide organizes the evidence for each category of sleep disorders separately, based on the positions of the AASM, the Polish Sleep Research Society, and current meta-analyses. No marketing. With specific numbers, dosages, and indications of when CBD makes sense and when you need medical diagnostics.

KEY INFORMATION
– A meta-analysis of 34 RCT studies confirms that CBD shortens sleep onset latency by 11.3 minutes and extends sleep by 23 minutes in individuals with psychogenic insomnia (Sleep Medicine Reviews, 2022).
– For chronic insomnia lasting more than 3 months, the first line of treatment remains cognitive-behavioral therapy CBT-I, not pharmacotherapy or supplementation (American Academy of Sleep Medicine, 2021).
– In obstructive sleep apnea (OSA), AASM advises against the use of cannabinoids; the gold standard is CPAP (AASM Position Statement, 2018).
– CBD works best for insomnia with an anxiety component, parasomnias, and sleep disorders accompanying PTSD; dose 25-75 mg in the evening.
– A medical consultation is necessary for insomnia lasting >3 months, snoring with apneas, excessive daytime sleepiness, and seizures during sleep.

/blog/czy-cbd-pomaga-na-sen/ a detailed guide on the mechanism and dosing of CBD in insomnia

Why are sleep disorders not a single illness?

The International Classification of Sleep Disorders ICSD-3 distinguishes 7 main categories and over 60 disease entities (American Academy of Sleep Medicine, 2014). Each requires a different diagnostic and therapeutic approach. Confusing insomnia with sleep apnea leads to erroneous treatment decisions and worsens the patient's condition. CBD works on some of them, but not all.

The first category is insomnia (insomniae), where the main problem is the inability to fall asleep or maintain sleep. The second is sleep-related breathing disorders, including OSA. The third is hypersomnia disorders (narcolepsy, idiopathic hypersomnia). The fourth is parasomnias, which are abnormal behaviors during sleep: nightmares, sleepwalking, REM sleep behavior disorder.

The fifth category includes movement disorders related to sleep, including restless legs syndrome (RLS) and periodic limb movements (PLMD). The sixth is circadian rhythm disorders, e.g., delayed sleep phase syndrome in adolescents. The seventh is isolated and symptomatic disorders. Diagnosing a specific entity often requires overnight polysomnography.

How common are sleep disorders in Poland?

In a Polish population study, symptoms of insomnia were reported by 50.5% of adults, with 23.2% meeting the criteria for clinical insomnia (Journal of Sleep Research, 2020). The Polish Sleep Research Society (PTBS) estimates that OSA affects about 7.5% of adult men and 5% of women, with 80% of cases remaining undiagnosed (Polish Sleep Research Society, 2020).

Restless legs syndrome (RLS) occurs in 5-10% of the adult population, with a predominance of women (Sleep Medicine, 2011). Narcolepsy affects about 0.02-0.05% of the population, and NREM parasomnias (sleepwalking, night terrors) are significantly more common in children (15-17%) than in adults (2-4%). Recurrent nightmares occur in 4-5% of adults, often in the context of PTSD.

These are significant statistics because they show that a „sleep problem” in the general population does not automatically mean insomnia. About 1 in 10 people complaining of fatigue and poor sleep quality actually have undiagnosed sleep apnea. For them, CBD will not only be unhelpful but may even exacerbate the problem by masking the need for CPAP treatment.

What are the most common types of insomnia?

Sleep medicine distinguishes several phenotypes of insomnia that respond to different therapies. Psychogenic insomnia (anxiety-related): difficulties falling asleep arise from racing thoughts and anticipatory anxiety. This is where CBD works strongest. Sleep maintenance insomnia: the patient falls asleep easily but wakes up at 3-4 AM. Often associated with depression, alcohol, or nocturnal hypoglycemia.

Paradoxical insomnia: the patient claims they did not sleep, although polysomnography shows 6+ hours of sleep. This is a form of distorted perception of one's own sleep, where CBD does not help because there is nothing to „improve”. Idiopathic insomnia: lasts from childhood, has a neurobiological basis, and requires pharmacotherapy under medical supervision. Situational insomnia: a reaction to a stressor (work, exam, loss), usually resolves spontaneously after 2-4 weeks.

Identifying the phenotype is crucial for selecting therapy. In practice, the doctor asks questions about sleep in the last 3 months, uses ISI (Insomnia Severity Index) questionnaires, and sleep diaries. Only then is a specific intervention recommended. Trying supplements on your own without this diagnostics is like shooting in the dark.

Polish population studies show that symptoms of insomnia occur in 50.5% of adults, and clinical insomnia is diagnosed in 23.2% (Journal of Sleep Research, 2020). OSA affects about 7.5% of men and 5% of women, with 80% remaining undiagnosed, which significantly complicates the assessment of whether the patient actually has insomnia or undiagnosed apnea (PTBS, 2020).

Does CBD treat primary insomnia?

CBD supports treatment but does not causally treat insomnia. According to the AASM guidelines from 2021, the gold standard for treating primary insomnia is cognitive-behavioral therapy for insomnia (CBT-I), not pharmacotherapy (American Academy of Sleep Medicine, 2021). CBD acts as an adjunct: it lowers evening cortisol, reduces pre-sleep anxiety, and facilitates sleep onset, which supports the effects of CBT-I.

A meta-analysis of 34 RCTs showed that CBD in doses of 25-160 mg reduces sleep onset latency by an average of 11.3 minutes and increases total sleep time by 23 minutes in individuals with insomnia (Sleep Medicine Reviews, 2022). The effect is moderate but clinically significant. Importantly, CBD does not generate tolerance over 8-12 weeks of observation, unlike benzodiazepines.

What exactly do clinical studies show?

A retrospective study by Shannon et al. on 72 patients with anxiety and insomnia found that 66.7% experienced improved sleep after 1 month of CBD supplementation at 25-75 mg daily (The Permanente Journal, 2019). The effect persisted for a 3-month observation period in about 60% of patients. Anxiety decreased in 79% of participants after just the first month.

A randomized study from 2023 on 80 people with insomnia tested 150 mg of CBD for 8 weeks. The active group achieved a 34% reduction in the ISI scale (placebo: 12%, p<0.01), and 72% of participants showed improvement in actigraphy (Frontiers in Psychiatry, 2023). This is one of the stronger RCTs to date, although still with a small sample.

An earlier review study by Babson in 2017 identified 28 publications linking cannabinoids to sleep quality. Most showed a positive effect of CBD on sleep in individuals with PTSD, chronic pain, and anxiety (Current Psychiatry Reports, 2017). However, Babson noted that much of this data comes from observational studies, not RCTs, which requires caution in interpretation.

Why is CBT-I the first line, not CBD?

Cognitive-behavioral therapy for insomnia (CBT-I) has higher long-term efficacy than any pharmacotherapy, with symptom remission in 70-80% of patients lasting 1-2 years after therapy ends (AASM, 2021). CBT-I works on the cognitive and behavioral mechanisms sustaining insomnia: sleep restriction, stimulus control, cognitive restructuring, and sleep hygiene.

Pharmacotherapy (including CBD) provides faster results but does not teach the patient „how to sleep healthily”. After discontinuation, relapse often occurs. The optimal model is CBT-I as a base + CBD or short-term pharmacotherapy as support in the first 2-4 weeks. In Poland, the availability of CBT-I is unfortunately limited, which leads patients to experiment with supplements on their own.

From our observations among customers of the CBD Hemp Store, the best results are achieved by individuals who combine CBD (25-50 mg in the evening) with sleep hygiene elements: a consistent sleep schedule, no screens an hour before bed, bedroom temperature 18-20°C, 4-7-8 breathing techniques. Simply supplementing with CBD without changing habits yields weaker and less lasting effects.

Does CBD help with obstructive sleep apnea (OSA)?

No, CBD does not help with obstructive sleep apnea. The American Academy of Sleep Medicine in an official statement from 2018 clearly advises against using cannabinoids in the treatment of OSA, citing interrupted studies on dronabinol (Journal of Clinical Sleep Medicine, 2018). The reason is simple: OSA is a mechanical problem of the upper airways, not a neurobiological sleep issue.

Obstructive sleep apnea involves repeated episodes of upper airway closure during sleep, lasting >10 seconds and causing a drop in saturation. In severe cases, the patient experiences >30 apneas per hour of sleep. This is a life-threatening condition associated with a 2-3 times higher risk of stroke, heart attack, and traffic accidents.

Why do cannabinoids not work in OSA?

A phase II study from 2018 tested dronabinol (synthetic THC) in 73 patients with OSA. The results were clinically insufficient to justify further research (Journal of Clinical Sleep Medicine, 2018). The reduction in the AHI index (apneas/hypopneas per hour) was minimal and unstable. The AASM then issued a position advising against the use of cannabinoids outside of clinical trials.

The key issue: OSA requires maintaining the patency of the upper airways during REM sleep, when the throat muscles naturally relax. Cannabinoids, including CBD, do not have a mechanism to influence the tone of the genioglossus muscle or the anatomy of the throat. THC additionally deepens sedation, which could theoretically worsen apneas in predisposed individuals.

The paradox is that patients with undiagnosed OSA often turn to CBD as a "natural remedy for insomnia" because they have issues with sleep fragmentation. CBD may subjectively improve sleep by masking symptoms, but it does not treat OSA. The long-term effect is delayed diagnosis and disease progression. Therefore, in cases of snoring, excessive daytime sleepiness, and waking up tired despite 8 hours of sleep, a polysomnographic study should always be conducted first, followed by supplementation.

How to recognize OSA instead of „ordinary” insomnia?

Red flags suggesting OSA: loud snoring, observed apneas by a partner, nighttime shortness of breath with awakening, morning headaches, excessive daytime sleepiness (Epworth scale >10), nocturnal frequent urination, treatment-resistant hypertension, BMI >30 (Polish Sleep Research Society, 2020). The more factors, the higher the likelihood of OSA.

Diagnosis involves polysomnography (PSG) or type 3 home polygraphy. The gold standard of treatment is CPAP (Continuous Positive Airway Pressure), which maintains positive pressure in the airways. Alternatives: MAD dental appliance, surgery (uvulopalatopharyngoplasty), weight reduction, side sleeping.

How does CBD affect restless legs syndrome (RLS)?

The evidence is preliminary but promising. In a case series published in Sleep Medicine, 6 patients with medication-resistant RLS experienced full remission of symptoms after 1-3 months of using medical cannabinoids (Sleep Medicine, 2017). However, this is just a case series, not an RCT, so the level of evidence is low. The first line remains dopaminergic pharmacotherapy and iron.

Restless legs syndrome is characterized by an irresistible urge to move the lower limbs, occurring in the evening and at night, relieved by movement. Many people describe it as „irritating tingling”, „water under the skin” or „bugs in the legs”. Symptoms disrupt falling asleep and fragment sleep. Iron deficiency in the CNS is a major pathophysiological factor.

What should be the first line of treatment for RLS?

The standard RLS therapy according to the International Restless Legs Syndrome Study Group includes: (1) iron supplementation when ferritin <75 ng/ml, (2) dopamine agonists (pramipexole, ropinirole), (3) alpha-2-delta ligands (gabapentin, pregabalin), (4) opioids in resistant cases (Sleep Medicine, 2018). CBD and other cannabinoids enter as an experimental option.

However, long-term dopaminergic medications have a problem called augmentation, which is a paradoxical worsening of symptoms after several years of therapy. In such patients, when standard options are exhausted, cannabinoids may be considered as a rescue therapy. In the cited 2017 study, all patients had RLS resistant to >2 medications, representing the most difficult population.

What mechanism could explain the effect of CBD in RLS?

There are several hypotheses. First, CBD modifies dopaminergic activity in the striatum, although not directly like pramipexole. Second, CBD has anti-inflammatory effects, and neuroinflammation is increasingly described in the pathophysiology of RLS. Third, it reduces anxiety and stress, which exacerbate RLS symptoms. Fourth, it reduces PLMS (periodic limb movements during sleep), improving sleep architecture.

In practice, CBD 25-50 mg in the evening, possibly with the addition of hemp flower with myrcene (a terpene with muscle-relaxing effects), is used by patients. The effect is significant for some, none for others. Always after consulting a neurologist, especially with coexisting dopaminergic medications.

In a case series, 6 patients with medication-resistant RLS all experienced full remission after 1-3 months of using medical cannabinoids (Sleep Medicine, 2017). These are single data points, not RCT evidence, so the first line remains iron supplementation with ferritin <75 ng/ml and dopamine agonists (IRLSSG Consensus, 2018).

What does CBD do for parasomnias and PTSD nightmares?

Parasomnias are abnormal behaviors during sleep: sleepwalking, night terrors, nightmares, REM sleep behavior disorder (RBD). The strongest data for cannabinoids concern PTSD nightmares. Nabilone (synthetic THC analog) at a dose of 0.5-3 mg before sleep reduces PTSD nightmares by 70-75% in a retrospective study (Journal of Clinical Sleep Medicine, 2015).

The mechanism is likely related to REM phase modulation. PTSD is characterized by excessive REM with high emotional activity, which generates nightmares. Cannabinoids slightly reduce REM, shifting sleep towards NREM, where the consolidation of traumatic memory is less intense. CBD itself has a weaker effect than nabilone but may be a safer option without the risk of psychoactivity.

How does CBD differ from nabilone in PTSD nightmares?

Nabilone is a full CB1 agonist, so it acts psychoactively and requires a special prescription. CBD acts indirectly, through 5-HT1A, FAAH, and GPR55, without psychoactive effects. In a small open-label study, 11 veterans with PTSD received 50-400 mg of CBD daily for 8 weeks, with a 28% reduction in nightmares and PTSD symptoms on the CAPS scale (Journal of Alternative and Complementary Medicine, 2019). Without a large RCT, we should not treat this as hard evidence.

In practice, for patients with PTSD and nightmares, CBD 30-50 mg in the evening, possibly with the addition of CBN 5 mg, is used as support for EMDR therapy or pharmacotherapy with prazosin (a standard medication for PTSD nightmares). The combination may be more effective than monotherapy. However, always under the supervision of a psychiatrist, especially with coexisting depression.

Is CBD safe for REM sleep behavior disorder (RBD)?

RBD is a disorder in which a person "acts out" dreams, performing violent movements, shouting, and hitting. In most patients, RBD is a prodrome of a neurodegenerative disease (Parkinson's, dementia with Lewy bodies, multiple system atrophy), which develops in 80-90% of patients within 10-15 years (Sleep Medicine Reviews, 2013).

The standard treatment is clonazepam 0.5-2 mg or high-dose melatonin 6-12 mg. There are no RCT data on CBD in RBD. Theoretically, by modulating REM, it could help, but high doses of THC worsen symptoms because THC intensifies dreams. Therefore, in individuals with RBD, we recommend only pure CBD isolate without THC, possibly broad spectrum, not full spectrum. Neurologist consultation is necessary.

NREM parasomnias (sleepwalking, night terrors in children) are not well studied in the context of CBD. In children, we do not recommend CBD supplementation for this indication. In adults with sporadic episodes of night terrors, the effects are anecdotal. The first line of treatment is sleep hygiene, reducing alcohol and anxiety, possibly low doses of clonazepam in severe cases.

How does CBD work in narcolepsy?

Narcolepsy is a rare hypersomnia disorder characterized by sudden daytime sleep attacks, cataplectic episodes of loss of muscle tone, and fragmentation of nighttime sleep. The cause is a deficiency of hypocretin in the hypothalamus. Treatment includes modafinil, pitolisant, and sodium oxybate for cataplexy. CBD is not a recommended treatment for narcolepsy due to the lack of RCTs in this population.

Interestingly, people with narcolepsy often experience nighttime sleep fragmentation, despite daytime sleep attacks. Here, CBD 25-50 mg in the evening is sometimes tried as support for nighttime sleep quality (Frontiers in Pharmacology, 2019). The effect is anecdotal, and potential interactions with medications (especially oxybate) require caution. The decision should always be made after consulting a neurologist.

What are the interactions of CBD with sleep medications?

CBD inhibits liver enzymes CYP3A4, CYP2C19, and CYP2C9, which modifies the metabolism of many medications (Frontiers in Pharmacology, 2020). In practice, this means that CBD at doses >300 mg may increase the concentration of benzodiazepines, z-drugs (zolpidem, zopiclone), warfarin, some antiepileptic and antidepressant medications. A medical consultation is necessary when co-administering medications.

In recreational doses for sleep (25-75 mg), the risk of interactions is low but not zero. Be particularly cautious with warfarin (monitoring INR), clobazam (an antiepileptic), tacrolimus (an immunosuppressant), and everolimus. With psychiatric medications like SSRIs, SNRIs, bupropion, interactions are usually mild, but it's worth discussing with a psychiatrist before introducing CBD.

Conversations with clients indicate that the most common issue is not actually drug interactions, but the combination of CBD with evening alcohol. Alcohol itself disrupts sleep architecture, fragments REM, and causes rebound anxiety at 3 AM. CBD taken "for calming" after a glass of wine does not help, as alcohol negates most of its sleep effects. Practical recommendation: if you drank alcohol in the evening, do not add CBD.

CBN, melatonin, and CBD: which works best?

CBN (cannabinol) is often marketed as the "strongest cannabinoid for sleep." The truth is more nuanced. In preclinical models, CBN shows weak sedative effects, about 10x weaker than THC (Cannabis and Cannabinoid Research, 2021). Clinical data in humans are limited. However, the combination of CBD+CBN shows a synergistic effect better than either alone.

In a 2024 study, 145 individuals with chronic insomnia used 50 mg of CBD + 5 mg of CBN in the evening for 6 weeks. 71% reported a reduction in sleep onset time, and 63% a decrease in nighttime awakenings (Cannabis and Cannabinoid Research, 2024). Mechanism: CBD acts anxiolytically and lowers cortisol, CBN enhances GABA-A receptor activation and CB1 receptor activation. The entourage effect with myrcene (a terpene present in the flower) further enhances sedation.

How does CBD compare to melatonin?

Melatonin and CBD act through different mechanisms, meaning they are complementary, not competitive. Melatonin resets the circadian rhythm by acting on MT1 and MT2 receptors in the suprachiasmatic nucleus. CBD lowers evening cortisol, reduces anxiety, and modulates GABA-A. A meta-analysis of 19 melatonin studies showed a reduction in sleep onset latency by an average of 7.06 minutes (PLOS ONE, 2013).

This is less than CBD (11.3 min). However, melatonin works better in circadian rhythm disorders (jet lag, delayed sleep phase syndrome), while CBD works better in anxiety-related insomnia. The best combination: melatonin 0.5-3 mg 2-3 hours before sleep (rhythm reset phase) + CBD 25-50 mg 45 minutes before sleep (anxiety calming phase) + magnesium glycinate 200-400 mg (GABA-A activation and muscle relaxation).

When to choose hemp flower instead of oil?

Full-spectrum hemp flower with natural CBD, CBN, and myrcene content provides the strongest sleep effect due to synergy (the entourage effect) (British Journal of Pharmacology, 2011). Administration forms: vaporization (effect in 5-15 minutes, bioavailability 30-45%) or infusion (effect after 60-90 minutes, lower bioavailability). Infusion from flower is a traditional Polish form among older individuals.

Flower has an advantage in insomnia with a pain component (myrcene has muscle-relaxing and analgesic effects) and in individuals who do not respond to CBD oil alone. Disadvantage: less precise dosing, requires a scale and knowledge of concentration. For beginners, oils are a simpler choice. For advanced users, flower may be a better tool.

How to determine the dose of CBD for a specific sleep disorder?

The therapeutic dosing range of CBD for sleep is between 15 and 160 mg in the evening, with most individuals finding the optimal zone in the range of 25-75 mg (The Permanente Journal, 2019). However, the dose depends on the type of disorder: different for anxiety-related insomnia, different for PTSD nightmares, different for RLS. Below is a practical protocol for each category.

Anxiety-related insomnia: start 15-25 mg, target 25-50 mg (anxiolytic doses). Chronic insomnia: 50-75 mg, sometimes up to 100 mg (sedative doses). PTSD nightmares: 30-50 mg, possibly + CBN 5 mg. Medication-resistant RLS: 25-50 mg + full-spectrum oil with myrcene. Parasomnias in adults: 15-25 mg, pure CBD isolate without THC.

What is the step-by-step protocol "start low, go slow"?

The classic titration protocol looks like this: days 1-4: 15 mg of CBD 45 minutes before sleep (6 drops of 5% oil). Days 5-8: 25 mg (10 drops of 5% or 5 drops of 10%). Days 9-14: 35-50 mg, if the effect is insufficient. From day 14: the optimal dose identified in this range. Days 21-28: possible increase to 75 mg for chronic insomnia.

An important nuance: cannabinoids act on an inverted U curve. After exceeding the optimal dose, the effect weakens, rather than increases (Project CBD, 2023). If at 75 mg you feel less than at 50 mg, that’s a sign you’ve exceeded the optimal zone. Back off to a lower dose. A larger dose does not always mean a stronger effect.

What form of CBD for a specific problem?

Sublingual oil (bioavailability 13-19%, effect 15-45 min) is best for falling asleep problems. Gummies and capsules (bioavailability 6-15%, effect 60-120 min, longer action) are better for waking up at night. Vaporizing flower (bioavailability 30-45%, effect 5-15 min) for individuals with evening anxiety attacks. Infusion from flower as a traditional form complementing sleep hygiene.

For individuals with respiratory issues (asthma, COPD), we avoid vaporization. For those with gastrointestinal problems, we are cautious with MCT oils (diarrhea, nausea). We check the COA certificates of each product to verify the actual CBD content and the absence of contaminants. In Poland, products with THC <0.2% are legal, so broad spectrum is a safe default option.

Sleep hygiene: what to do before reaching for CBD?

Sleep hygiene is the foundation of any insomnia and sleep disorder therapy. According to AASM 2021 guidelines, it is the first line of action, regardless of the cause (American Academy of Sleep Medicine, 2021). Studies show that good sleep hygiene can improve sleep quality by 15-25% without any medications or supplements. CBD without sleep hygiene is like filling a leaky bucket.

Key elements of sleep hygiene: a consistent sleep and wake time (±30 min, even on weekends), no screens 60 minutes before sleep (blue light inhibits melatonin), bedroom temperature 18-20°C, absolute darkness (black curtains or eye mask), silence (earplugs or white noise), no caffeine after 2 PM, no alcohol 3 hours before sleep, no intense exercise 3 hours before sleep.

What relaxation techniques work with CBD?

The 4-7-8 breathing technique (inhale for 4 seconds, hold for 7, exhale for 8) activates the parasympathetic nervous system and lowers heart rate by 10-15 bpm within 2-3 minutes. Progressive muscle relaxation (tensing and relaxing muscle groups from feet to head) reduces muscle tension in the body by 30-40% over 15 minutes. Body scan meditation allows for locating and relaxing areas of tension.

The combination of CBD 25 mg 45 minutes before sleep + 4-7-8 breathing technique after lying down works stronger than each element separately. CBD lowers cortisol and biochemically calms anxiety, while the breathing technique activates physiological relaxation. The synergistic effect leads to falling asleep 10-15 minutes faster for most people. This is a clinical observation, unvalidated RCT, but the mechanism is coherent.

Many of our clients ask, "Will CBD work for me?" Instead, it is worth asking: "Does my sleep hygiene give CBD a chance to work?" A person who looks at their phone until 2 AM, drinks coffee after lunch, and has a bedroom at 24°C will not fall asleep even after 100 mg of CBD. First hygiene, then supplementation, and finally prescription pharmacotherapy.

When to see a doctor instead of reaching for CBD?

A medical consultation is necessary for insomnia lasting more than 3 months, excessive daytime sleepiness limiting functioning, snoring with observed apneas, nocturnal seizures, and accompanying depression. The Polish Sleep Research Society recommends referral to a sleep medicine clinic or psychiatrist (PTBS, 2020). CBD does not replace medical diagnostics.

Specific red flags requiring urgent consultation: (1) observed apneas during sleep (risk of OSA), (2) cataplexy or "sudden sleep attacks" (risk of narcolepsy), (3) violent movements with shouting during sleep (risk of RBD, prodrome of neurodegenerative disease), (4) suicidal thoughts and insomnia (risk of depression), (5) nighttime seizures or bedwetting (epilepsy, OSA), (6) insomnia after age 65 with cognitive decline.

What does a consultation with a sleep medicine doctor look like?

A sleep medicine doctor will conduct a detailed sleep interview (often lasting 45-60 minutes), assess questionnaires (ISI, Epworth, STOP-BANG), analyze a 2-week sleep diary. They will then recommend polysomnography in a sleep lab or home polygraphy. Polysomnography lasts one night, measuring EEG, EMG, EKG, airflow, saturation, respiratory movements, and limb micromovements.

After establishing a diagnosis, specific treatment is introduced: CPAP for OSA, CBT-I for primary insomnia, dopamine and iron for RLS, modafinil for narcolepsy, clonazepam for RBD. CBD may then be considered as an adjunct, but not as a substitute. The doctor may also rule out other causes: hypothyroidism, depression, vitamin D deficiency, which correlates with insomnia.

According to the AASM guidelines from 2021, the gold standard for treating chronic insomnia is cognitive-behavioral therapy CBT-I, not pharmacotherapy (American Academy of Sleep Medicine, 2021). In obstructive sleep apnea, the gold standard is CPAP, and cannabinoids are advised against in the official AASM position (AASM Position Statement, 2018). CBD has an adjunct role, not a primary treatment.

How does CBD compare to classic sleep medications?

Benzodiazepines (lorazepam, diazepam, alprazolam) act quickly and strongly but generate tolerance within 2-4 weeks and physical dependence. After discontinuation, rebound insomnia worse than before treatment is observed. Z-drugs (zolpidem, zopiclone) have a lower but still significant risk of dependence. WHO and NICE recommend benzodiazepines only short-term, for 2-4 weeks (WHO Essential Medicines, 2021).

CBD, according to the WHO assessment from 2018, is "well tolerated, with no potential for dependence" at doses up to 1500 mg per day (World Health Organization, 2018). It does not generate tolerance in 8-12 weeks of observation, does not impair REM phase, and does not cause a "hangover" the next day. This is a fundamental advantage over benzodiazepines, especially in older adults, where benzos increase the risk of falls and dementia.

What about OTC medications: doxylamine, diphenhydramine?

Over-the-counter medications like doxylamine (in Poland, products like Noctis) or diphenhydramine work by blocking histamine H1. They shorten sleep onset latency by an average of 8-15 minutes but have numerous side effects: dry mouth, constipation, urinary retention, confusion in older individuals (anticholinergic effect). Studies show that long-term use increases the risk of dementia (JAMA Internal Medicine, 2015).

CBD does not have anticholinergic effects, making it a safer long-term alternative, especially in individuals over 65. Doxylamine works as a short-term therapy (up to 2 weeks), while CBD serves as a long-term supplement. Comparing effects: doxylamine is faster and stronger, CBD is milder and without cognitive risk. The choice depends on the clinical context.

When do herbal alternatives provide a real effect?

Valerian (Valeriana officinalis) has a meta-analysis of 18 RCTs showing moderate reduction in sleep onset latency and improvement in subjective sleep quality (American Journal of Medicine, 2006). Lemon balm, lavender, chamomile have weaker but consistent data. Hops enhance the action of valerian. Passionflower supports anxiety calming.

In practice, a combination of CBD 25 mg + valerian 300 mg + lemon balm 200 mg in the evening is safe and enhances the effect of each ingredient. We avoid combining with melatonin in high doses (>5 mg), as it may cause hyperpolarization and a paradoxical effect. General rule: the simpler the combination, the easier it is to determine what actually works for a specific person.

The most common mistakes with CBD for sleep disorders

Studies among CBD users show that 40-60% do not achieve the expected effect, mainly due to application errors (Project CBD, 2023). The most common mistakes: too low a dose, irregularity, incorrect form, neglecting sleep hygiene, combining with alcohol, expecting immediate effects.

It must also be mentioned that there is a strategic error: treating CBD as a substitute for a doctor. A person with undiagnosed sleep apnea who "treats" themselves with CBD for a year delays proper diagnosis. The costs: progression of cardiovascular diseases, increased risk of stroke, excessive daytime sleepiness, traffic accidents. CBD does not replace polysomnography or specialist consultation.

What are typical dosing traps?

The first trap: too low a dose. 5-10 mg of CBD rarely suffices to see any effect on sleep. This is below the therapeutic threshold. The second trap: too high a starting dose. 100 mg in a person who has never used CBD before sometimes causes paradoxical stimulation (high doses activate 5-HT1A in a nonlinear way). The third trap: irregularity. CBD requires 2-4 weeks of continuous use for the full effect on sleep architecture to manifest.

The fourth trap: wrong timing of intake. Oil 30 minutes before sleep, gummies 90-120 minutes before sleep. The fifth: cheap products without certificates. The CBD market in Poland is full of products where the actual CBD content is 30-70% lower than declared. The sixth: combining with medications without consultation. Especially warfarin, clobazam, tacrolimus. The seventh: lack of sleep hygiene, which undermines the effects of supplementation.

Why is it not worth overdoing the dose?

A higher dose does not always mean a better effect. Cannabinoids have a bell-shaped dose-response curve, so after exceeding the optimal zone, the effect weakens (Project CBD, 2023). Above 100 mg of CBD, some individuals may experience morning drowsiness, dry mouth, diarrhea, and general fatigue. Above 300 mg, CYP3A4 inhibition and drug interactions may occur.

For the safety of long-term supplementation, we recommend the optimal dose, not the maximum. Most people do not need more than 25-50 mg in the evening. Financial savings are an additional benefit. A 5% oil with 500 mg lasts an average of 20-30 days at a dose of 25 mg, while a 10% oil lasts 20-25 days at a dose of 50 mg. Daily cost calculation: 3-5 PLN.

Is CBD safe for pregnant women and children for sleep?

No, CBD is not recommended for pregnant women, breastfeeding mothers, and children under 18. There is insufficient safety research, and the FDA, EMA, and Polish GIS warn against self-supplementation in these groups (FDA, 2023). Insomnia during pregnancy and breastfeeding requires consultation with a gynecologist or psychiatrist.

In pregnant women, insomnia affects 75-80% in the third trimester. First line: sleep hygiene, relaxation techniques, side sleeping (left side), magnesium 300-400 mg of glycinate if there are no contraindications. Pharmacotherapy only under the supervision of a gynecologist. CBD crosses the placenta and into breast milk, and the long-term effects on the fetus are unknown.

What about insomnia in children and adolescents?

In children, insomnia most often results from anxiety disorders, circadian rhythm disorders (in teenagers), or behavioral disorders. The gold standard is behavioral modification and age-appropriate sleep hygiene. CBD in children is recommended only for specific indications (Dravet, Lennox-Gastaut), by prescription and under the supervision of a pediatric neurologist.

In adolescents with delayed sleep phase (falling asleep after 2-3 AM), light therapy at 6:30-7:30 AM, chronotherapy, and low doses of melatonin 0.3-0.5 mg 5 hours before sleep are effective. CBD is not recommended here due to the lack of studies in the pediatric population. Parents self-supplementing CBD for their child risk drug interactions and unknown effects on the developing brain.

When is CBD ineffective for sleep?

About 30-40% of CBD users for sleep do not achieve significant subjective improvement (The Permanente Journal, 2019). This is not a product flaw but a consequence of the fact that not every insomnia has an anxiety or cortisol background. In individuals with organic, endocrine, or respiratory insomnia, CBD has nothing to act on biologically.

Typical situations when CBD fails: (1) undiagnosed sleep apnea, (2) untreated hypothyroidism, (3) iron deficiency with RLS, (4) severe depression requiring SSRIs, (5) bipolar affective disorder, (6) paradoxical insomnia, (7) substance dependence (alcohol, sleeping pills) with rebound insomnia. In each of these cases, CBD may alleviate symptoms but does not address the cause.

What to do when CBD does not help?

After 4-6 weeks of regular use of CBD 25-75 mg in the evening without effect, one should stop and conduct a thorough diagnosis. Step 1: sleep diary for 2 weeks. Step 2: ISI, Epworth, STOP-BANG, PHQ-9 questionnaires for depression. Step 3: blood tests (TSH, ferritin, vitamin D, B12, fasting glucose). Step 4: sleep medicine consultation considering polysomnography.

Sometimes the solution is to change strategies: add CBN, change form (from oil to flower), combine with melatonin, CBT-I session. Other times, it turns out that short-term pharmacotherapy is needed (trazodone, doxepin, mirtazapine in low doses) under psychiatric supervision. CBD is just one of the tools, not a universal solution.

In our observation, the most common mistake is "testing" CBD for 3-5 days and declaring that it "does not work." CBD needs 2-4 weeks of regular use to stabilize levels in tissues and influence sleep architecture. The first night may yield a subjective placebo effect or nothing, which means nothing. A full assessment requires at least 4 weeks.

The most common questions about CBD and sleep disorders (FAQ)

Does CBD cure insomnia, or just alleviate symptoms?

CBD alleviates symptoms and supports sleep hygiene, but does not causally treat insomnia. According to AASM guidelines, the gold standard for treating primary insomnia remains cognitive-behavioral therapy CBT-I (American Academy of Sleep Medicine, 2021). CBD works as an adjunct for individuals with pre-sleep anxiety, reducing sleep onset latency by an average of 11.3 minutes (Sleep Medicine Reviews, 2022).

Does CBD help with obstructive sleep apnea (OSA)?

No, CBD or cannabinoids in general are not recommended in OSA. The American Academy of Sleep Medicine in its official statement from 2018 advises against their use, as the study on dronabinol was interrupted due to insufficient efficacy (AASM Position Statement, 2018). The gold standard remains CPAP, dental devices, or surgery. CBD does not mechanically open the upper airways.

Does CBD help with restless legs syndrome (RLS)?

The evidence is preliminary. In a series of 6 patients with medication-resistant RLS, all experienced remission of symptoms after 1-3 months of using cannabinoids (Sleep Medicine, 2017). However, this is a case series, not RCT. The first line of treatment for RLS is iron supplementation with ferritin <75 ng/ml, dopamine agonists, and gabapentin. CBD is considered after exhausting standard options.

Does CBD disrupt the REM sleep phase?

No, at doses of 25-75 mg, CBD does not significantly disrupt the REM phase, unlike benzodiazepines and THC (Frontiers in Pharmacology, 2018). Moreover, nabilone (synthetic cannabinoid) helps with PTSD nightmares by modulating REM (Journal of Clinical Sleep Medicine, 2015). Individuals with REM sleep behavior disorder (RBD) should use CBD isolate without THC.

When to see a doctor for insomnia instead of trying CBD?

Whenever insomnia lasts more than 3 months, is accompanied by snoring with apneas, excessive daytime sleepiness, seizures during sleep, or depression (Polish Sleep Research Society, 2020). An assessment for OSA (polysomnography), RLS, narcolepsy, and depression is necessary. CBD can be safely used for situational or anxiety-related insomnia, but does not replace diagnostics for organic disorders.

Which CBD product to choose for different sleep disorders?

For anxiety-related insomnia: broad spectrum CBD oil 5-10% at a dose of 25-50 mg in the evening (The Permanente Journal, 2019). For parasomnias and nightmares: CBD isolate without THC, 15-30 mg. For insomnia with pain: full-spectrum oil or hemp flower with CBN and myrcene. For generalized anxiety: CBG 15% in the morning + CBD in the evening. Avoid combinations with high THC in mental disorders.

Summary and next steps

CBD has a place in the therapeutic arsenal for treating insomnia and other sleep disorders, but it is not a universal solution. The best evidence concerns anxiety-related insomnia, where CBD 25-75 mg in the evening reduces sleep onset latency by 11.3 minutes and increases sleep by 23 minutes (Sleep Medicine Reviews, 2022). For sleep apnea, CBD will not help, and the AASM explicitly advises against cannabinoids (AASM, 2018).

Practical next steps: (1) assess the phenotype of your insomnia, (2) implement sleep hygiene for 2 weeks, (3) if needed, add CBD 15-25 mg as a start, increase every 4-5 days, (4) observe effects for 4 weeks, (5) if no improvement or red flags occur, medical consultation. For chronic insomnia, CBT-I remains the gold standard, CBD is an adjunct, not a substitute.

/blog/czy-cbd-pomaga-na-sen/ a detailed guide on the neurobiological mechanism, dosing, and forms of CBD exclusively in the context of insomnia

Author: Michał Waluk, u Bucha – CBD Hemp Store. Article written based on the current guidelines of the American Academy of Sleep Medicine (AASM) 2021, AASM's position on medical marijuana and cannabinoids 2018, guidelines from the Polish Sleep Research Society 2020, meta-analysis from Sleep Medicine Reviews 2022, clinical studies from The Permanente Journal 2019, and Frontiers in Psychiatry 2023.